{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T13:40:15Z","timestamp":1733060415450,"version":"3.30.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2831,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:sec>\n            <jats:title\/>\n          <\/jats:sec>","DOI":"10.1002\/hep.22097","type":"journal-article","created":{"date-parts":[[2007,11,28]],"date-time":"2007-11-28T16:48:22Z","timestamp":1196268502000},"page":"1685-1687","update-policy":"http:\/\/dx.doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Therapy with vasoconstrictor drugs in cirrhosis: The time has arrived"],"prefix":"10.1097","volume":"46","author":[{"given":"Pere","family":"Gin\u00e8s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Guevara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-5-20241201","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(03)14903-3","article-title":"Hepatorenal syndrome.","volume":"362","author":"Gines","year":"2003","journal-title":"Lancet"},{"key":"R2-5-20241201","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/hep.20687","article-title":"MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation.","volume":"41","author":"Alessandria","year":"2005","journal-title":"Hepatology"},{"key":"R4-5-20241201","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1056\/NEJMra035021","article-title":"Current conceptsmanagement of cirrhosis and ascites.","volume":"350","author":"Gines","year":"2004","journal-title":"N Engl J Med"},{"key":"R5-5-20241201","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/hep.21094","article-title":"The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond.","volume":"43","author":"Moreau","year":"2006","journal-title":"Hepatology"},{"key":"R6-5-20241201","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.jhep.2007.02.001","article-title":"Advances in the pathogenesis and treatment of type1 and type2 hepatorenal syndrome.","volume":"46","author":"Arroyo","year":"2007","journal-title":"J Hepatol"},{"key":"R7-5-20241201","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0140-6736(56)90149-0","article-title":"Electrolyte and circulatory changes in terminal liver failure.","volume":"271","author":"Hecker","year":"1956","journal-title":"Lancet"},{"key":"R8-5-20241201","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1749-6632.1970.tb37014.x","article-title":"Relationship of plasma volume, portal hypertension, ascites, and renal sodium retention in cirrhosisoverflow theory of ascites formation.","volume":"170","author":"Lieberman","year":"1970","journal-title":"Ann N Y Acad Sci"},{"key":"R10-5-20241201","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/0016-5085(82)90329-8","article-title":"Peritoneovenous shunt in the management of ascites and the hepatorenalsyndrome.","volume":"82","author":"Epstein","year":"1982","journal-title":"Gastroenterology"},{"key":"R11-5-20241201","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.1840080532","article-title":"Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.","volume":"8","author":"Schrier","year":"1988","journal-title":"Hepatology"},{"key":"R12-5-20241201","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/ki.1985.142","article-title":"Interrelationship between cardiacoutput and vascularresistance as determinants of effective arterial bloodvolume in cirrhoticpatients.","volume":"28","author":"Shapiro","year":"1985","journal-title":"Kidney Int"},{"key":"R13-5-20241201","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/hep.1840060213","article-title":"Sodiumexcretion in advanced cirrhosiseffect of expansion of central bloodvolume and suppression of plasmaaldosterone.","volume":"6","author":"Nicholls","year":"1986","journal-title":"Hepatology"},{"key":"R14-5-20241201","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/hep.510270107","article-title":"Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion.","volume":"27","author":"Guevara","year":"1998","journal-title":"Hepatology"},{"key":"R15-5-20241201","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/hep.510300430","article-title":"Longterm therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine.","volume":"30","author":"Gulberg","year":"1999","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"R16-5-20241201","first-page":"694A","article-title":"A prospective, randomized, double blind, placebocontrolled trial of terlipressin for type 1 hepatorenal syndrome (HRS). Abstract LB6.","volume":"44","author":"Sanyal","year":"2006","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"R17-5-20241201","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/S0168-8278(07)61680-8","article-title":"Terlipressin and albumin versus albumin alone in patients with cirrhosis and hepatorenal syndrome. A randomized, comparative study. Abstract 82.","volume":"46","author":"MartinLlahi","year":"2007","journal-title":"J Hepatol"},{"key":"R18-5-20241201","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1053\/jhep.2002.34343","article-title":"Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study.","volume":"36","author":"Duvoux","year":"2002","journal-title":"Hepatology"},{"key":"R19-5-20241201","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jhep.2007.04.010","article-title":"Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study.","volume":"47","author":"Alessandria","year":"2007","journal-title":"J Hepatol"},{"key":"R20-5-20241201","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/00042737-200212000-00013","article-title":"Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2.","volume":"14","author":"Alessandria","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"pt 1","key":"R21-5-20241201","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1053\/jhep.2002.35819","article-title":"Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.","volume":"36","author":"Ortega","year":"2002","journal-title":"Hepatology"},{"key":"R22-5-20241201","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1053\/gast.2002.37073","article-title":"Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis.","volume":"123","author":"Gines","year":"2002","journal-title":"Gastroenterology"},{"key":"R24-5-20241201","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/hep.510280407","article-title":"Acute effects of the oral administration of midodrine, an alphaadrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.","volume":"28","author":"Angeli","year":"1998","journal-title":"Hepatology"},{"key":"R25-5-20241201","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jhep.2006.09.012","article-title":"Effects of a 7day treatment with midodrine in nonazotemic cirrhotic patients with and without ascites.","volume":"46","author":"Kalambokis","year":"2007","journal-title":"J Hepatol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.22097","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200712000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T13:12:09Z","timestamp":1733058729000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200712000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.22097","relation":{},"ISSN":["0270-9139"],"issn-type":[{"type":"print","value":"0270-9139"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}